Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023

SELL
$5.88 - $9.59 $16.8 Million - $27.4 Million
-2,857,143 Reduced 48.38%
3,048,257 $26.6 Million
Q4 2021

Feb 18, 2022

BUY
$3.23 - $4.6 $19.1 Million - $27.2 Million
5,905,400 New
5,905,400 $20 Million

Others Institutions Holding CBAY

About CymaBay Therapeutics, Inc.


  • Ticker CBAY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 84,677,904
  • Description
  • CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...
More about CBAY
Track This Portfolio

Track Tcg Crossover Management, LLC Portfolio

Follow Tcg Crossover Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tcg Crossover Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Tcg Crossover Management, LLC with notifications on news.